Compare · DFTX vs GLAS
DFTX vs GLAS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Glass House Brands Inc. Subordinate Voting Shares (GLAS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and GLAS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.47B, about 24.4x GLAS ($183.0M).
- DFTX has hit the wire 6 times in the past 4 weeks while GLAS has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for GLAS).
- Company
- Definium Therapeutics Inc.
- Glass House Brands Inc. Subordinate Voting Shares
- Price
- -
- -
- Market cap
- $4.47B
- $183.0M
- 1M return
- -2.66%
- -
- 1Y return
- +184.56%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 8
- 0
Glass House Brands Inc. Subordinate Voting Shares
Glass House is one of the fastest-growing cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. Whether it be through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell and Mama Sue Wellness, Glass House is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
Latest GLAS
No recent items for Glass House Brands Inc. Subordinate Voting Shares.